ChartRow logo
Data provided bySource: Twelve Data
BBIO
$76.80-0.72%
as of close, Nov 17, 2026
☾ AH $76.80 -0.72%
PeersASNDRVMDARGXINCYRPRXGH
Share this page

BBIO financial statements

The full income statement, balance sheet, and cash-flow statement for BridgeBio Pharma Inc. (BBIO), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

5Y CAGR +127.4%5Y CAGR +127.4%YoY +192.6%
$945.5M TTM$353.2M Q3 '26
FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Gross profit

YoY +191.5%
$892M TTM$332.7M Q3 '26
FY21FY22FY23FY24FY25TTM
Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y n/m5Y n/mYoY n/m
−$364.2M TTM−$11.6M Q3 '26
FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y n/m5Y n/mYoY n/m
−$565.8M TTM−$56.7M Q3 '26
FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$2.90 TTM−$0.42 Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating cash flow

5Y n/m5Y n/mYoY n/m
−$369M TTM−$44.2M Q3 '26
FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Capital expenditure

5Y CAGR −32.0%5Y CAGR −32.0%YoY −38.3%
$835K TTM$290K Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y n/m5Y n/mYoY n/m
−$369.8M TTM−$44.5M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Shares (diluted)

5Y +62.3%5Y +62.3%YoY +2.2%
195M TTM196M Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Every BBIO chart on Trends →

Shares outstanding (point-in-time)

2024-09 189.0M2024-12 190.2M2025-03 189.9M2025-06 191.2M2025-09 192.7M2025-12 193.9M2026-03 195.9M2026-06 195.5M2026-09 194.8M+3.1% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Revenue502M+126.3%222M+2285.3%9.30M-88.0%77.6M+11.4%69.7M+745.1%
481M+120.7%218M+3079.6%6.86M-90.8%74.2M+11.4%66.6M
Cost of revenue21.0M+440.5%3.88M+58.5%2.45M-28.8%3.43M+10.3%3.11M
Research & development452M-10.8%506M+11.1%456M+14.1%399M-11.4%451M+33.8%
Selling, general & administrative531M+83.9%289M+91.9%151M+5.2%143M-25.5%192M+31.9%
Restructuring—15.6M+96.9%7.93M-81.9%43.8M0.00
Amortization of intangibles2.70M+12.5%2.40M+0.0%2.40M+0.0%2.40M-7.7%2.60M
Operating income-523M+11.7%-593M+2.4%-607M-18.6%-512M+11.2%-577M-21.5%
Interest expense53.1M-41.6%91.0M+11.9%81.3M+1.1%80.4M+72.0%46.8M+27.6%
Interest & investment income19.9M+15.1%17.2M-4.4%18.0M+139.2%7.54M+565.7%1.13M-71.8%
Other non-operating income43.1M+250.9%12.3M-29.3%17.4M+331.6%-7.50M-120.9%35.8M+2092.4%
Equity-method income-72.6M-132.8%-31.2M0.000.00—
Gain (loss) on equity securities0.00-100.0%8.14M-55.6%18.3M+322.7%-8.22M-127.5%29.9M
Pre-tax income-733M-35.1%-542M+17.0%-653M-34.8%-485M—
Income tax435K-62.3%1.15M0.000.00—
-725M-35.3%-536M+16.7%-643M-33.7%-481M+14.5%-563M-25.4%
Net income to non-controlling interest-8.01M-5.6%-7.58M+24.5%-10.0M-189.7%-3.47M+85.5%-23.9M+57.9%
Net income to common-725M-35.3%-536M+16.7%-643M-33.7%-481M+14.5%-563M-25.4%
-$3.78-31.3%-$2.88+27.1%-$3.95-21.2%-$3.26+16.4%-$3.90-2.6%
EPS (basic)-$3.78-31.3%-$2.88+27.1%-$3.95-21.2%-$3.26+16.4%-$3.90-2.6%
Weighted-avg shares (basic)192M+2.9%186M+14.3%163M+10.4%147M+2.2%144M+22.3%
Weighted-avg shares (diluted)192M+2.9%186M+14.3%163M+10.4%147M+2.2%144M+22.3%
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
798M+10.7%721M+50.9%478M-13.0%549M-38.3%889M+38.3%
Cash & equivalents570M-16.3%681M+81.2%376M-0.2%377M-4.3%394M+10.6%
Short-term investments—0.000.00-100.0%51.6M-86.9%394M+56.9%
Accounts receivable139M+2853.1%4.72M+169.7%1.75M——
Inventory26.8M0.00———
Prepaid expenses44.1M+26.4%34.9M+43.5%24.3M+10.9%21.9M-32.1%32.3M-9.7%
936M+1.8%919M+68.3%546M-12.3%623M-38.5%1.01B+43.9%
Property, plant & equipment5.37M-23.5%7.01M-40.7%11.8M-18.9%14.6M-51.5%30.1M+47.9%
Operating lease right-of-use8.15M+41.3%5.77M-28.2%8.03M-24.8%10.7M-32.9%15.9M-3.6%
Intangible assets28.1M+17.3%23.9M-9.1%26.3M-8.3%28.7M-36.1%44.9M
Other non-current assets16.7M-8.2%18.2M-19.6%22.6M+11.9%20.2M-38.8%33.0M+38.0%
288M+86.5%154M+7.3%144M+18.5%121M-10.1%135M+41.2%
Accounts payable36.2M+276.7%9.62M-9.7%10.7M-7.8%11.6M-2.7%11.9M+32.9%
Deferred revenue7.19M-50.8%14.6M+139.6%6.10M-25.3%8.16M0.00
Current lease liability6.19M+37.4%4.51M+9.2%4.13M+12.3%3.67M-25.6%4.94M+30.1%
Other current liabilities120M+263.5%33.1M———
Finance lease liability (current)
————295K+130.5%
3.01B+26.7%2.38B+25.8%1.89B+1.1%1.87B-0.6%1.88B+215.3%
Long-term debt2.01B+359.0%437M-2.0%446M+3.6%431M+0.1%431M+366.1%
Deferred revenue (non-current)13.1M-23.5%17.1M+358.7%3.73M——
Non-current lease liability3.81M-18.8%4.70M-47.7%8.98M-26.8%12.3M-29.6%17.4M+18.7%
Operating lease liability (total)10.0M+8.7%9.20M-29.8%13.1M-17.8%15.9M-28.7%22.4M+21.1%
Finance lease liability (total)
————1.54M-9.5%
Finance lease liability
————1.25M-20.9%
Other non-current liabilities244K-14.7%286K-94.9%5.63M-78.9%26.6M+20.7%22.1M+131.8%
-2.09B-42.1%-1.47B-8.4%-1.35B-7.9%-1.25B-44.1%-870M-1603.1%
Preferred stock0.000.00———
Common stock202K+3.1%196K+8.3%181K+15.3%157K+1.9%154K+23.2%
Additional paid-in capital2.06B+8.1%1.90B+28.5%1.48B+57.8%939M+11.5%842M-17.6%
Retained earnings-3.82B-23.4%-3.10B-20.9%-2.56B-33.5%-1.92B-33.5%-1.44B-61.7%
Treasury stock323M+17.6%275M+0.0%275M+0.0%275M+0.0%275M+266.7%
Accumulated other comprehensive income12.0K+50.0%8.00K-74.2%31.0K+109.5%-328K-148.5%-132K-168.8%
Non-controlling interest10.6M+4.4%10.2M-9.7%11.2M-0.3%11.3M+230.7%3.41M-92.9%
Total equity incl. non-controlling-2.08B-42.4%-1.46B-8.5%-1.34B-8.0%-1.24B-43.4%-867M-916.0%
Total liabilities & equity936M+1.8%919M+68.3%546M-12.3%623M-38.5%1.01B+43.9%
Common shares issued202M+3.1%196M+8.3%181M+15.6%157M+2.1%154M+22.6%
Common shares outstanding195M+2.5%190M+8.5%175M+16.2%151M+2.2%147M+19.9%
Shares outstanding (cover)194M+1.9%190M+8.2%176M+16.2%151M+2.6%148M-0.9%
Treasury shares7.60M+22.7%6.19M+0.0%6.19M+0.0%6.19M+0.0%6.19M+156.4%
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
-446M+14.4%-521M+1.3%-528M-25.8%-419M+15.8%-498M-24.6%
Depreciation & amortization5.43M-10.6%6.08M-6.5%6.49M-4.1%6.77M+15.9%5.84M+301.3%
Intangible amortization2.70M+12.5%2.40M+0.0%2.40M+0.0%2.40M-7.7%2.60M
Share-based compensation133M+38.9%95.8M-11.9%109M+18.7%91.6M-8.0%99.5M+70.2%
Deferred income taxes0.000.000.00——
Change in receivables135M+4434.6%2.97M+119.4%-15.3M-1.0%-15.2M—
Change in inventory25.3M0.000.00——
Change in payables26.6M+1659.9%1.51M-45.6%2.78M+896.6%-349K-112.3%2.83M+485.4%
-24.5M-140.3%60.8M+12.5%54.0M-88.1%453M+325.6%-201M-279.0%
Capital expenditure1.10M+17.6%933K-28.6%1.31M-72.9%4.82M-63.6%13.2M+76.2%
Free cash flow-447M+14.3%-522M+1.4%-529M-24.7%-424M+17.0%-511M-25.5%
Acquisitions0.000.000.000.000.00
Other investing activities———0.000.00-100.0%
359M-52.0%748M+65.8%452M+3537.9%-13.1M-101.8%736M+64.7%
Long-term debt issued0.00-100.0%450M0.000.00-100.0%456M
Long-term debt repaid—473M0.00-100.0%20.5M-83.5%124M
Common stock issued0.00-100.0%315M-30.0%450M+9170.6%4.85M0.00
Common stock repurchased48.3M0.000.000.00-100.0%200M+166.7%
Dividends paid0.000.000.000.000.00
Other financing activities—0.000.00-100.0%837K0.00
Net change in cash-111M-138.5%289M+1402.4%-22.2M-208.0%20.5M-45.6%37.7M+783.0%
Interest paid43.7M-52.2%91.3M+49.5%61.1M+12.2%54.4M+82.9%29.8M+94.3%
Income taxes paid1.20M0.000.00——
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap14.9B+185.7%5.21B-25.7%7.02B+516.6%1.14B-53.7%2.46B-71.9%
P/S29.7×+26.3%23.5×-96.8%744.9×+5698.4%12.8×-63.6%35.3×-96.7%
Source filing10-K10-K10-K10-K10-K
Fiscal yearCEOTotal, as reportedActually paidOther executives, average$100 in the stock$100 in peers
FY2025Dr.Kumar$14.9M$75.4M$3.3M$108.00$125.00
FY2024Dr.Kumar$15.6M−$2.7M$6.1M$39.00$93.00
FY2023Dr.Kumar$12.2M$70.1M$6.7M$57.00$94.00
FY2022Dr.Kumar$6.7M−$11.3M$3M$11.00$90.00
FY2021Dr.Kumar$25.6M−$132.8M$8.7M$23.00$100.00
FY2020Dr. Kumar$10.1M$151.1M$4.8M——

From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.

About this data

Source: BBIO’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all BBIO filings on SEC EDGAR → Not investment advice.